CAR T-cell therapy: Clinical Trials

19 trials of CAR T-cell therapy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 active not recruiting, 7 recruiting, 2 suspended, 1 not yet recruiting. 13 Phase 1, 7 Phase 2, 1 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 113Active not recruiting 7, Recruiting 3, Suspended 2, Unknown 1
Phase 27Active not recruiting 3, Recruiting 3, Not yet recruiting 1
Early Phase 11Recruiting 1

Follow CAR T-cell therapy: new trials by email Literature Review of CAR T-cell therapy trials Research Report on CAR T-cell therapy

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
NT-I7, CAR T-cell therapy - Large B-cell Lymphoma
Phase 1RecruitingWashington University School of Medicine242026-03-122026-09-29
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
Odronextamab, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Phase 2RecruitingUniversity of Washington272025-09-042026-11-18
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
Chimeric Antigen Receptor T-Cell Therapy, Odronextamab - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Phase 2RecruitingUniversity of California, Davis342025-08-072026-07-08
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Echocardiography - Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4
Phase 1RecruitingCity of Hope Medical Center272025-06-172026-10-22
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
Phase 2RecruitingMayo Clinic412025-04-022026-10-20
CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors
CAR T-cell therapy, Glofitamab, Obinutuzumab - Large B-cell Lymphoma
Phase 2Not yet recruitingRuijin Hospital452024-09-012024-08-22
A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis
KYV-101 (Biological) - 0.33 ×10^8 cells, KYV-101 (Biological) - 1 ×10^8 cells, Chemotherapy: cyclophosphamide (CYC) - Progressive Multiple Sclerosis
Phase 1Active not recruitingBruce Cree102024-06-202026-08-10
Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation
Biopsy, Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy - Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder
Phase 1SuspendedCity of Hope Medical Center272024-02-192026-11-18
Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Early Phase 1RecruitingCity of Hope Medical Center92023-07-202026-02-04
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma
Chimeric Antigen Receptor T-Cell Therapy, Quality-of-Life Assessment, Questionnaire Administration - Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Phase 2Active not recruitingNorthwestern University242022-03-212024-10-16
Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Phase 1SuspendedUniversity of California, Davis362021-09-172026-11-16
CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia
CAR T-cell therapy - Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia
Phase 1RecruitingNational University Hospital, Singapore202021-09-082021-09-14
ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.
CAR T-cell therapy - Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia
Phase 1UnknownNational University Hospital, Singapore402021-04-282021-09-09
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - CD19 Positive, CD20 Positive
Phase 1Active not recruitingJonsson Comprehensive Cancer Center242019-10-042026-08-20
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
Chimeric Antigen Receptor T-Cell Therapy - Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
Phase 1Active not recruitingCity of Hope Medical Center242018-11-272026-08-12
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia
Phase 1 / Phase 2Active not recruitingFred Hutchinson Cancer Center532017-12-052026-06-22
Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies
Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - B Acute Lymphoblastic Leukemia, CD19 Positive
Phase 1Active not recruitingStanford University332017-10-202026-06-30
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - B Acute Lymphoblastic Leukemia, CD19 Positive
Phase 1Active not recruitingStanford University562017-09-012025-11-18
CAR-T Cell Therapy Targeting to CD19 for R/R ALL
CAR T-cell therapy - Acute Lymphoblastic Leukemia With Failed Remission
Phase 1 / Phase 2Active not recruitingThe First Affiliated Hospital of Soochow University1962015-12-012026-06-04

Conditions studied

Lymphoma, Large B-Cell, Diffuse (8)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (4)  ·  Lymphoma, Follicular (3)  ·  Burkitt Lymphoma (2)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2)  ·  Lymphoma, Mantle-Cell (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Neoplasm, Residual (2)  ·  Astrocytoma (1)  ·  Brain Neoplasms (1)  ·  Breast Neoplasms (1)  ·  Bronchiolitis Obliterans Syndrome (1)  ·  Glioblastoma (1)  ·  Hematologic Diseases (1)  ·  Leukemia (1)

Sponsors

City of Hope Medical Center (4)  ·  National University Hospital, Singapore (2)  ·  Stanford University (2)  ·  University of California, Davis (2)  ·  Bruce Cree (1)  ·  Fred Hutchinson Cancer Center (1)  ·  Jonsson Comprehensive Cancer Center (1)  ·  Mayo Clinic (1)  ·  Northwestern University (1)  ·  Ruijin Hospital (1)  ·  The First Affiliated Hospital of Soochow University (1)  ·  University of Washington (1)  ·  Washington University School of Medicine (1)

Countries

United States (15)  ·  China (2)  ·  Singapore (2)

Top investigators

Allen Yeoh, M.D (2)  ·  Dario Campana, M.D, PhD (2)  ·  Amandeep Salhotra (1)  ·  Behnam Badie (1)  ·  Bruce Cree, MD, PhD, MAS (1)  ·  Claire Tiger, MD, PhD (1)  ·  Crystal Mackall (1)  ·  Depei Wu, M.D., Ph.D. (1)  ·  Jana L Portnow (1)  ·  Joseph M Tuscano, MD (1)  ·  Lori Muffly, MD, MS (1)  ·  Mazyar Shadman (1)  ·  Mehrdad Abedi (1)  ·  Mengyang Di, MD, PhD (1)  ·  Reem Karmali, MD (1)

Results publications

PMID 34515338, PMID 32399214, PMID 32929049, PMID 34312556, PMID 34889384, PMID 35013456, PMID 37095120, PMID 38968138

NIH funding

P30CA033572 (3), P30CA093373 (2), P30CA060553 (1), R01CA286488 (1)